0.16(2.39%) Volume: 2,921,383 4:00PM EDT| Market Cap : 3.84 B | Enterprise Value : 3.81 B | P/E(TTM) : | P/B : 1.79 |
|---|
OPK has been successfully added into Your Stock Email Alerts list.
You can manage your stock email alerts here.
OPK has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
GuruFocus Financial Strength Rank measures how strong a companyÂ’s financial situation is. It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
| vs
industry |
vs
history |
||
|---|---|---|---|
| Cash-to-Debt | 1.31 |
OPK's Cash-to-Debt is ranked lower than
55% of the 815 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 2.12 vs. OPK: 1.31 ) Ranked among companies with meaningful Cash-to-Debt only. |
OPK'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.13 Med: 18 Max: No Debt Current: 1.31 |
| Equity-to-Asset | 0.76 |
OPK's Equity-to-Asset is ranked higher than
70% of the 739 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 0.63 vs. OPK: 0.76 ) Ranked among companies with meaningful Equity-to-Asset only. |
OPK'
s Equity-to-Asset Range Over the Past 10 Years
Min: -0.41 Med: 0.69 Max: 0.96 Current: 0.76 |
| Piotroski F-Score: 3 |
|
| Altman Z-Score: 3.67 |
|
| Beneish M-Score: -2.36 |
|
| WACC vs ROIC |
1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•
| vs
industry |
vs
history |
||
|---|---|---|---|
| Operating Margin % | -7.13 |
OPK's Operating Margin % is ranked lower than
77% of the 767 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 7.94 vs. OPK: -7.13 ) Ranked among companies with meaningful Operating Margin % only. |
OPK'
s Operating Margin % Range Over the Past 10 Years
Min: -31624.44 Med: -82.69 Max: -6 Current: -7.13 |
| Net Margin % | -3.59 |
OPK's Net Margin % is ranked lower than
75% of the 769 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 6.26 vs. OPK: -3.59 ) Ranked among companies with meaningful Net Margin % only. |
OPK'
s Net Margin % Range Over the Past 10 Years
Min: -31688.9 Med: -92.47 Max: -2.05 Current: -3.59 |
| ROE % | -2.14 |
OPK's ROE % is ranked lower than
71% of the 792 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 6.84 vs. OPK: -2.14 ) Ranked among companies with meaningful ROE % only. |
OPK'
s ROE % Range Over the Past 10 Years
Min: -3196.93 Med: -20.87 Max: -1.23 Current: -2.14 |
| ROA % | -1.59 |
OPK's ROA % is ranked lower than
71% of the 821 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 3.58 vs. OPK: -1.59 ) Ranked among companies with meaningful ROA % only. |
OPK'
s ROA % Range Over the Past 10 Years
Min: -1352.71 Med: -13.26 Max: -0.83 Current: -1.59 |
| ROC (Joel Greenblatt) % | -36.79 |
OPK's ROC (Joel Greenblatt) % is ranked lower than
79% of the 807 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 13.07 vs. OPK: -36.79 ) Ranked among companies with meaningful ROC (Joel Greenblatt) % only. |
OPK'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -130662.93 Med: -258.52 Max: -36.79 Current: -36.79 |
| 3-Year Revenue Growth Rate | 101.30 |
OPK's 3-Year Revenue Growth Rate is ranked higher than
98% of the 640 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 5.20 vs. OPK: 101.30 ) Ranked among companies with meaningful 3-Year Revenue Growth Rate only. |
OPK'
s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0 Med: 26 Max: 152 Current: 101.3 |
| 3-Year EPS without NRI Growth Rate | -46.30 |
OPK's 3-Year EPS without NRI Growth Rate is ranked lower than
94% of the 580 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 7.90 vs. OPK: -46.30 ) Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only. |
OPK'
s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -69.4 Med: -9.3 Max: 152.4 Current: -46.3 |
What is Peter Lynch Charts )| Industry: | Drug Manufacturers » Drug Manufacturers - Specialty & Generic NAICS: 325412 SIC: 2834 | |
|---|---|---|
| Compare: | NAS:AKRX, OTCPK:STDAF, NYSE:MNK, NYSE:CTLT, NYSE:TARO, OTCPK:HKMPY, NAS:IRWD, NAS:MDCO, NYSE:PTHN, NAS:ENDP, OTCPK:HYPMY, NYSE:VRX, NAS:SUPN, OTCPK:EVTCY, NAS:RDUS, NAS:HZNP, NAS:PCRX, NAS:PAHC, NAS:MNTA, NAS:EGRX » details | |
| Traded in other countries: | XCY.Germany, OPK.Israel, OPK.Mexico, | |
| Headquarter Location: | USA |
| vs
industry |
vs
history |
||
|---|---|---|---|
| PB Ratio | 1.79 |
OPK's PB Ratio is ranked higher than
69% of the 761 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 2.88 vs. OPK: 1.79 ) Ranked among companies with meaningful PB Ratio only. |
OPK'
s PB Ratio Range Over the Past 10 Years
Min: 1.68 Med: 8.44 Max: 800 Current: 1.79 |
| PS Ratio | 3.08 |
OPK's PS Ratio is ranked lower than
52% of the 743 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 2.96 vs. OPK: 3.08 ) Ranked among companies with meaningful PS Ratio only. |
OPK'
s PS Ratio Range Over the Past 10 Years
Min: 2.87 Med: 31.62 Max: 158.13 Current: 3.08 |
| Price-to-Operating-Cash-Flow | 571.66 |
OPK's Price-to-Operating-Cash-Flow is ranked lower than
98% of the 281 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 19.13 vs. OPK: 571.66 ) Ranked among companies with meaningful Price-to-Operating-Cash-Flow only. |
OPK'
s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 20.6 Med: 43.78 Max: 676.67 Current: 571.66 |
| EV-to-EBITDA | 136.11 |
OPK's EV-to-EBITDA is ranked lower than
96% of the 591 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 17.55 vs. OPK: 136.11 ) Ranked among companies with meaningful EV-to-EBITDA only. |
OPK'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -146.6 Med: -34 Max: 539.9 Current: 136.11 |
| Current Ratio | 1.74 |
OPK's Current Ratio is ranked lower than
65% of the 795 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 2.40 vs. OPK: 1.74 ) Ranked among companies with meaningful Current Ratio only. |
OPK'
s Current Ratio Range Over the Past 10 Years
Min: 0.88 Med: 5.3 Max: 415 Current: 1.74 |
| Quick Ratio | 1.56 |
OPK's Quick Ratio is ranked lower than
57% of the 795 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 1.84 vs. OPK: 1.56 ) Ranked among companies with meaningful Quick Ratio only. |
OPK'
s Quick Ratio Range Over the Past 10 Years
Min: 0.48 Med: 4.75 Max: 415 Current: 1.56 |
| Days Inventory | 26.02 |
OPK's Days Inventory is ranked higher than
93% of the 713 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 117.36 vs. OPK: 26.02 ) Ranked among companies with meaningful Days Inventory only. |
OPK'
s Days Inventory Range Over the Past 10 Years
Min: 25.94 Med: 191.87 Max: 500.07 Current: 26.02 |
| Days Sales Outstanding | 71.08 |
OPK's Days Sales Outstanding is ranked higher than
54% of the 651 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 74.70 vs. OPK: 71.08 ) Ranked among companies with meaningful Days Sales Outstanding only. |
OPK'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 38.86 Med: 153.78 Max: 727.85 Current: 71.08 |
| Days Payable | 43.98 |
OPK's Days Payable is ranked lower than
73% of the 597 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 70.86 vs. OPK: 43.98 ) Ranked among companies with meaningful Days Payable only. |
OPK'
s Days Payable Range Over the Past 10 Years
Min: 31.85 Med: 108.04 Max: 1499.3 Current: 43.98 |
| vs
industry |
vs
history |
||
|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -10.60 |
OPK's 3-Year Average Share Buyback Ratio is ranked lower than
71% of the 477 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: -4.30 vs. OPK: -10.60 ) Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only. |
OPK'
s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -146.3 Med: -14.4 Max: 0.4 Current: -10.6 |
| vs
industry |
vs
history |
||
|---|---|---|---|
| Price-to-Tangible-Book | 343.00 |
OPK's Price-to-Tangible-Book is ranked lower than
100% of the 701 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 3.54 vs. OPK: 343.00 ) Ranked among companies with meaningful Price-to-Tangible-Book only. |
OPK'
s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.35 Med: 10.28 Max: 850 Current: 343 |
| Price-to-Intrinsic-Value-Projected-FCF | 2.59 | ||
| Price-to-Median-PS-Value | 0.10 |
OPK's Price-to-Median-PS-Value is ranked higher than
99% of the 718 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 1.08 vs. OPK: 0.10 ) Ranked among companies with meaningful Price-to-Median-PS-Value only. |
OPK'
s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.1 Med: 1.29 Max: 30 Current: 0.1 |
| Earnings Yield (Greenblatt) % | -1.92 |
OPK's Earnings Yield (Greenblatt) % is ranked lower than
74% of the 820 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 2.97 vs. OPK: -1.92 ) Ranked among companies with meaningful Earnings Yield (Greenblatt) % only. |
OPK'
s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -26.7 Med: -2.7 Max: 0.5 Current: -1.92 |
| Revenue (TTM) (Mil) $ | 1,226.72 |
|---|---|
| EPS (TTM) $ | -0.10 |
| Beta | 2.15 |
| Short Percentage of Float | 22.01% |
| 52-Week Range $ | 5.99 - 12.15 |
| Shares Outstanding (Mil) | 559.39 |
| Dec17 | Dec18 | Dec19 | |
|---|---|---|---|
| Revenue (Mil $) | 1,244 | 1,389 | 1,550 |
| EPS ($) | -0.28 | -0.17 | 0.03 |
| EPS without NRI ($) | -0.28 | -0.17 | 0.03 |
| EPS Growth Rate (Future 3Y To 5Y Estimate) | 12.00% | ||
| Dividends per Share ($) | |||
GF Chat
Excel Add-In GURUF
API
My Portfolios
Create New Portfolio
Portfolio Contest
My Gurus
Personalize
My Gurus
Email Alerts
Stock PDF
RSS
Website
Filings
Manual of Stocks™ Web APP